Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) Share Price and News

Price

Movement

( )

(20 mins delayed)

52 Week Range

-

 
1 Year Return

 

Fisher & Paykel Healthcare Corp Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $19.99 billion
P/E Ratio 57.43
Dividend Yield 1.12%
Shares Outstanding 586.26 million
Earnings per share 0.639
Dividend per share 0.39
Year To Date Return -2.52%
Earnings Yield 1.74%
Franking -
Share Price

Day Change

( )

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

  • Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)
    Latest News

    Two brokers analysing stocks.
    Healthcare Shares

    Why does Macquarie think Fisher & Paykel shares are a buy?

    Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

    Read more »

    Yellow rising arrow on a brick wall with a man on a ladder.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a rough start to the trading week for investors this Monday.

    Read more »

    Contented looking man leans back in his chair at his desk and smiles.
    Broker Notes

    Leading brokers name 3 ASX shares to buy today

    Here's why brokers believe that now could be the time to snap up these shares.

    Read more »

    Ten happy friends leaping in the air outdoors.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    Investors finished the trading week on a high note this Friday.

    Read more »

    Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
    Share Fallers

    Why ALS, Fisher & Paykel Healthcare, IPD, and Predictive Discovery shares are falling today

    These shares are having a tough time on hump day. But why?

    Read more »

    Woman presenting financial report on large screen in conference room.
    Healthcare Shares

    Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

    Will the ASX 200 healthcare stock continue to outperform?

    Read more »

    Man with backpack spreading his arms out and soaking in the sun.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a mild session for ASX shares, but still a positive one.

    Read more »

    Five young people sit in a row having fun and interacting with their mobile phones.
    Share Market News

    5 'particularly interesting' ASX All Ords stocks to buy amid the Trump tariff mayhem

    A leading expert reveals five quality ASX All Ords stocks with little or no Trump tariff impact.

    Read more »

    Health professional working on his laptop.
    Healthcare Shares

    Trump 2.0: Macquarie's take on the winners and losers in Australian healthcare

    Let's see what the broker is saying about these healthcare stocks.

    Read more »

    A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
    Healthcare Shares

    Should I buy Fisher & Paykel or ResMed shares?

    Let's see which of these two names could be best buys.

    Read more »

    Silhouettes of nine people climbing a steep mountain to the top at sunset, and helping each other along the way.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    The ASX was rocked by 'Liberation Day' this Thursday.

    Read more »

    A woman's hand draws a stylised 'Top Ten' on a projected surface.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a big session for ASX shares this hump day.

    Read more »

    Frequently Asked Questions

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    05 Dec 2024 $0.1678 0.00% Interim 18 Dec 2024
    26 Jun 2024 $0.2137 0.00% Final 10 Jul 2024
    05 Dec 2023 $0.0318 0.00% Supplemental 18 Dec 2023
    05 Dec 2023 $0.1800 0.00% Interim 18 Dec 2023
    26 Jun 2023 $0.0406 0.00% Supplemental 07 Jul 2023
    26 Jun 2023 $0.2117 0.00% Interim 07 Jul 2023
    08 Dec 2022 $0.0309 0.00% Supplemental 21 Dec 2022
    08 Dec 2022 $0.1645 0.00% Interim 21 Dec 2022
    22 Jun 2022 $0.0397 0.00% Supplemental 06 Jul 2022
    22 Jun 2022 $0.2029 0.00% Final 06 Jul 2022
    02 Dec 2021 $0.0300 0.00% Supplemental 15 Dec 2021
    02 Dec 2021 $0.1784 0.00% Interim 15 Dec 2021
    24 Jun 2021 $0.0388 0.00% Supplemental 07 Jul 2021
    24 Jun 2021 $0.2046 0.00% Final 07 Jul 2021
    03 Dec 2020 $0.0282 0.00% Supplemental 16 Dec 2020
    03 Dec 2020 $0.1510 0.00% Interim 16 Dec 2020
    06 Jul 2020 $0.0274 0.00% Supplemental 17 Jul 2020
    06 Jul 2020 $0.1463 0.00% Final 17 Jul 2020
    06 Dec 2019 $0.0212 0.00% Supplemental 19 Dec 2019
    06 Dec 2019 $0.1148 0.00% Interim 19 Dec 2019
    13 Jun 2019 $0.1287 0.00% Final 05 Jul 2019
    07 Dec 2018 $0.0172 0.00% Supplemental 21 Dec 2018
    07 Dec 2018 $0.0921 0.00% Interim 21 Dec 2018
    21 Jun 2018 $0.0221 0.00% Supplemental 06 Jul 2018
    21 Jun 2018 $0.1151 0.00% Final 06 Jul 2018
    05 Dec 2017 $0.0154 0.00% Supplemental 20 Dec 2017
    05 Dec 2017 $0.7802 0.00% Interim 20 Dec 2017
    15 Jun 2017 $0.0199 0.00% Supplemental 07 Jul 2017
    15 Jun 2017 $0.1074 0.00% Final 07 Jul 2017
    06 Dec 2016 $0.0789 0.00% Interim 21 Dec 2016
    16 Jun 2016 $0.0955 0.00% Final 08 Jul 2016
    09 Dec 2015 $0.0629 0.00% Interim 23 Dec 2015
    17 Jun 2015 $0.0710 0.00% Final 10 Jul 2015
    03 Dec 2014 $0.0537 0.00% Interim 19 Dec 2014
    18 Jun 2014 $0.0650 0.00% Final 04 Jul 2014
    04 Dec 2013 $0.0491 0.00% Interim 19 Dec 2013
    19 Jun 2013 $0.0586 0.00% Final 05 Jul 2013
    29 Nov 2012 $0.0426 0.00% Interim 14 Dec 2012
    20 Jun 2012 $0.0550 0.00% Final 06 Jul 2012
    30 Nov 2011 $0.0413 0.00% Interim 16 Dec 2011
    22 Jun 2011 $0.0534 0.00% Final 08 Jul 2011
    01 Dec 2010 $0.0418 0.00% Interim 17 Dec 2010
    28 Jun 2010 $0.0000 0.00% Final 09 Jul 2010
    10 Dec 2009 $0.0301 0.00% Interim 18 Dec 2009
    22 Jun 2009 $0.0476 0.00% Final 06 Jul 2009
    04 Dec 2008 $0.0095 0.00% Supplemental 12 Dec 2008
    04 Dec 2008 $0.0000 0.00% Interim 12 Dec 2008
    19 Jun 2008 $0.0062 0.00% Supplemental 27 Jun 2008
    19 Jun 2008 $0.0700 0.00% Final 27 Jun 2008
    06 Dec 2007 $0.0095 0.00% Supplemental 14 Dec 2007
    06 Dec 2007 $0.0473 0.00% Interim 14 Dec 2007
    21 Jun 2007 $0.0124 0.00% Supplemental 29 Jun 2007
    21 Jun 2007 $0.0700 0.00% Final 29 Jun 2007
    23 Nov 2006 $0.0095 0.00% Supplemental 01 Dec 2006
    23 Nov 2006 $0.0540 0.00% Interim 01 Dec 2006
    19 Jun 2006 $0.0124 0.00% Supplemental 28 Jun 2006
    19 Jun 2006 $0.0700 0.00% Final 28 Jun 2006
    02 Dec 2005 $0.0095 0.00% Supplemental 09 Dec 2005
    02 Dec 2005 $0.0540 0.00% Interim 09 Dec 2005
    08 Jun 2005 $0.0102 0.00% Supplemental 17 Jun 2005
    08 Jun 2005 $0.0580 0.00% Final 17 Jun 2005
    24 Nov 2004 $0.0088 0.00% Supplemental 03 Dec 2004
    24 Nov 2004 $0.0500 0.00% Interim 03 Dec 2004
    14 Jun 2004 $0.0494 0.00% Supplemental 18 Jun 2004
    14 Jun 2004 $0.2800 0.00% Final 18 Jun 2004

    FPH ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Fisher & Paykel Healthcare Corp Ltd

    Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) is among the world's major designers and manufacturers of respiratory devices. These include products and systems covering in-hospital respiratory care, acute care, and the treatment of obstructive sleep apnea.

    The New Zealand-based company earns around 42% of its revenue from the US market and around 30% in Europe. Its hospital products account for about 65% of its revenue with its at-home sleep apnea devices and other respiratory aids accounting for the rest.

    Fisher & Paykel invests more than 10% of its operating revenue into its own research and development and has thousands of patents and pending applications. The company has manufacturing facilities in both New Zealand and Mexico. 

    FPH Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    06 Jun 2025 $34.07 $-0.65 -1.87% 399,995 $34.39 $34.73 $33.84
    05 Jun 2025 $34.72 $0.32 0.93% 334,564 $34.51 $34.72 $34.26
    04 Jun 2025 $34.40 $0.05 0.15% 405,518 $34.32 $34.48 $33.77
    03 Jun 2025 $34.35 $-0.49 -1.41% 837,019 $34.50 $34.83 $33.76
    02 Jun 2025 $34.84 $0.91 2.68% 578,841 $34.21 $34.89 $33.81
    30 May 2025 $33.93 $1.70 5.27% 1,071,451 $32.37 $34.02 $32.23
    29 May 2025 $32.23 $-0.26 -0.80% 524,294 $32.98 $33.25 $32.00
    28 May 2025 $32.49 $-1.63 -4.78% 790,461 $33.96 $34.05 $32.25
    27 May 2025 $34.12 $0.79 2.37% 259,859 $33.75 $34.23 $33.50
    26 May 2025 $33.33 $-0.06 -0.18% 224,095 $33.22 $33.65 $32.96
    23 May 2025 $33.39 $-0.62 -1.82% 221,008 $33.58 $33.63 $33.03
    22 May 2025 $34.01 $0.17 0.50% 256,347 $33.61 $34.01 $33.26
    21 May 2025 $33.84 $1.01 3.08% 235,428 $33.35 $33.99 $33.20
    20 May 2025 $32.83 $-0.66 -1.97% 521,098 $32.98 $33.32 $31.96
    19 May 2025 $33.49 $-0.60 -1.76% 332,871 $34.09 $34.09 $32.95
    16 May 2025 $34.09 $-0.10 -0.29% 342,690 $34.36 $34.36 $33.90
    15 May 2025 $34.19 $1.03 3.11% 422,697 $33.33 $34.37 $33.12
    14 May 2025 $33.16 $0.07 0.21% 317,777 $33.13 $33.48 $32.97
    13 May 2025 $33.09 $0.56 1.72% 298,907 $33.18 $33.38 $32.88

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    17 Feb 2025 Graham McLean Buy 1,000 $32,300
    On-market trade.
    12 Sep 2024 Graham McLean Buy 800 $27,932
    As advised by the company. Purchase of Ordinary Shares, As per announcement on 17-09-2024

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Michael Grenfell Daniell Non-Executive Director Nov 2001
    Mr Daniell was Managing Director and Chief Executive Officer of Fisher & Paykel Healthcare from 2001 to 2016. He was General Manager of Fisher & Paykel's medical division from 1990 to 2001 and previously held various technical management and product design roles within the company. Mike is a director of Cochlear Limited, Tait International Limited and the Medical Research Commercialisation Fund. Sir Michael was named a Knight Companion of the New Zealand Order of Merit in June 2021. Bachelor of Engineering (Hons) COMMITTEE RESPONSIBILITIES: Chair, Quality, Safety & Regulatory Committee Member, People & Remuneration Committee
    Mr Lewis George Gradon Chief Executive OfficerManaging Director Apr 2016
    Mr Gradon spent 15 years as Senior Vice President, Products & Technology, and six years as General Manager, Research & Development. During his 42-year tenure with Fisher & Paykel Healthcare, he has held engineering positions overseeing the development of range of products as well the development of manufacturing, quality, intellectual property, supply chain and clinical research functions.
    Mr Neville Mitchell Non-Executive DirectorNon-Executive Chairman Nov 2018
    Mr Mitchell was Chief Financial Officer and Company Secretary of Cochlear Limited between 1995 and 2017. He is a director of Sonic Healthcare and Sigma Healthcare, and a former director of The Board of Tax, South Eastern Sydney Local Health District, Osprey Medical and Sirtex Medical. Previously, he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100, and Chairman, Standing Committee (Accounting and Auditing) for the Australian Securities and Investments Commission. He is member of Risk Committee, People Committee and Quality, Safety & Regulatory Committee.
    Dr Lisa Margaret McIntyre Non-Executive Director Oct 2021
    Dr McIntyre is a director of The University of Sydney, Studiosity, Nanosonics and Baymatob. She has previously been a director of a range of health entities, including those in healthcare insurance, clinical service delivery and medical research and innovation. Lisa spent 20 years as a senior strategy partner with LEK Consulting providing advice to companies in North America, Asia and Australia. She is Chair of People Committee and member of Risk Committee.
    Mr Andrew Mark Cross Non-Executive Director Oct 2024
    Mr Cross chairs the board of Chorus and is a director of Xero. He is a board member of Accident Compensation Corporation (ACC) and chair of the ACC Investment Committee. He is a former chair of Milford Asset Management and a former director of Z Energy, Genesis Energy and Argosy Property. Mark previously held executive investment banking positions with Deutsche Bank and Lloyds Corporate Finance/ Southpac Corporation, where he was an advisor to companies across a range of sectors. He is Chair of Risk Committee.
    Ms Philippa (Pip) Mary Greenwood Non-Executive Director Jun 2017
    Ms Greenwood is chair of both Westpac New Zealand Limited and The a2 Milk Company Limited. She was previously a director of Vulcan Steel and Spark New Zealand and served as a member of the New Zealand Takeovers Panel from 2007 to 2011. Pip was a partner at Russell McVeagh between 2001 and 2019 and served as the firm's board chair. She is member of Risk Committee and People Committee.
    Mr Graham McLean Non-Executive Director Oct 2023
    Mr McLean is chair of both CleanSpace Technology and Universal Biosensors. He previously spent 16 years as an executive at leading medical device manufacturer Stryker Corporation, most recently as President of the Asia Pacific region situated in Hong Kong and Singapore. Prior to joining Stryker, Graham had finance, audit and commercial positions at Lion Nathan, McVitie's and Unilever. He is member of Risk Committee.
    Dr Cather Simpson Non-Executive Director Jun 2022
    Dr Simpson is a professor of physics and chemical sciences at the University of Auckland, CEO of Orbis Diagnostics and a partner at Pacific Channel, with experience in lasers and photonics. She is Vice President of the International Society for Optics and Photonics (SPIE) and a member of the Academy Executive Committee of the Royal Society Te Aparangi. Cather is a co founder of three hard-tech start-ups, including Engender Technologies, where she served as Chief Science Officer from 2011 to 2021. She founded and directed the Photon Factory at the University of Auckland in 2010. She is member of Quality, Safety & Regulatory Committee.
    Ms Raelene Leonard Company Secretary
    -
    Lyndal York Chief Financial Officer
    -
    Andy Niccol Chief Operating Officer
    -
    Raelene Leonard Company Secretary
    -
    Desh Edirisuriya General Manager New Zealand Operations
    -
    Marcus Driller Vice President Corporate
    -
    Nicola Talbot Vice President Human Resources
    -
    Nicholas Fourie Vice President Information & Communication Technology
    -
    Jonti Rhodes Vice President Network Design Facilities Infrastructure & Sustainability
    -
    Dr Andrew Somervell Vice President Products & Technology
    -
    Brian Schultz Vice President Quality Safety & Regulatory Affairs
    -
    Justin Callahan Vice President Sales & Marketing
    -
    Winston Fong Vice President Surgical Technologies
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Nominees (New Zealand) Limited R601127393 72,851,413 12.43%
    JPMorgan Nominees Australia Pty Limited 57,561,758 9.82%
    HSBC Custody Nominees (Australia) Limited 56,987,614 9.72%
    HSBC Nominees (New Zealand) Limited R601127385 49,522,756 8.45%
    Citicorp Nominees Pty Limited 45,014,138 7.68%
    JPMorgan Chase Bank 38,164,940 6.51%
    BNP Paribas Nominees NZ Limited R601338998 34,567,359 5.95%
    Citibank Nominees (NZ) Ltd 26,303,930 4.49%
    Custodial Services Limited 18,854,845 3.22%
    Tea Custodians Limited 17,923,982 3.06%
    New Zealand Superannuation Fund Nominees Limited 14,683,602 2.51%
    Premier Nominees Limited 7,842,613 1.34%
    Accident Compensation Corporation 7,828,198 1.34%
    New Zealand Permanent Trustees Limited 6,561,373 1.12%
    Public Trust 6,119,187 1.04%
    New Zealand Depository Nominee 5,708,620 0.97%
    FNZ Custodians Limited 5,446,374 0.93%
    JBWere (NZ) Nominees Limited 5,233,917 0.89%
    National Nominees Limited 4,773,913 0.81%
    BNP Paribas Nominees NZ Limited R601339005 4,582,882 0.78%

    Profile

    since

    Note